Study phase		Baseline screening	Study period			End	Discontinuation
Study week		Weeks −2 to 0	Week 0	Week 12, 24, 36	At clinical relapse	Week 48	Weeks 0–48
Inclusion/exclusion		●					
Demographics		●					
Enrollment		●					
Research drug administration					←	→	
Research drug dosage					←	→	
Concomitant medications/combination therapy		←					→
Adverse events			←				→
Vital signs		●		●	●	●	●
DAS28 joint assessment		●		●	●	●	●
VAS assessments • Patient pain • Patient global assessment		●		●	●	●	●
VAS assessment Physician global assessement		●		●	●	●	●
DAS28-ESR, DAS28-CRP		●		●	●	●	●
HAQ-DI		●		●	●	●	●
Laboratory	Blood chemistry	●		●	●	●	●
	Hematology	●		●	●	●	●
	CRP・RF・ACPA・MMP-3	●		●	●	●	●
	Cytokines	●		●	●	●	●
Musculoskeletal ultrasound		●			●	●	●
X-ray		●				●	

Supplemental Figure S1. Study schedule for the outcome measurements. ACPA, anti-cyclic citrullinated peptide antibody; CRP, C-reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MMP-3, matrix metalloproteinase-3; RF, rheumatoid factor; VAS: Visual Analog Scale.

Supplemental Table S1. The participating institutions

No.	Institution name
1	Nagasaki University Hospital
2	Asahi General Hospital
3	Chiba-East Hospital
4	Eiraku Clinic
5	Fukushima Medical University Hospital
6	Hamanomachi Hospital
7	Japanese Red Cross Nagasaki Genbaku Hospital
8	Kagawa University Hospital
9	Kindai University Hospital
10	University of Miyazaki Hospital
11	Miyazaki Zenjinkai Hospital
12	Nagasaki Kita Hospital
13	Osaka Metropolitan University Hospital
14	Osaka Medical and Pharmaceutical University Hospital
15	Sagawa Akira Rheumatology Clinic
16	Sasebo Chuo Hospital
17	Tobata General Hospital
18	Utazu Hospital
19	Yoshitama Clinic for Rheumatic Diseases

Supplemental Table S2. Baseline characteristics

Subject numbers	Case 1	Case 2	Case 3	Case 4	Case 5
Age, years	74	49	73	63	51
Sex	Male	Female	Female	Male	Female
Height, cm	170	156.2	163.1	162	161
Weight, kg	63.6	47	53	71	64
Disease Duration, year	8	10	N/A	6	19
Rheumatoid factor-positive	Yes	Yes	Yes	Yes	Yes
Anti-cyclic citrullinated peptide antibody-positive	Yes	Yes	Yes	Yes	Yes
Smoking history	Former smoker	Never smoked	Former smoker	Current smoker	Former smoker
Complications	Hypertension	None	Systemic lupus erythematosus, Sjögren's syndrome	Angina pectoris, gastroesophageal reflux disease, hypercholesterolemia, insomnia	None
Duration of remission or low disease activity, week	180	516	144	169	116
CT-P13 dose, mg/kg	6	3	3	3	6
CT-P13 dose interval, week	8	14	12	8	8
Pretreatment for RA	None	None	None	Glucocorticoid	Bucillamine, tofacitinib
Concomitant medications for RA					
Methotrexate dose, mg/week	8	8	6	10	8
Prednisolone dose, mg/day	None	None	5	None	None

N/A, not available; RA, rheumatoid arthritis